EYPT News

EyePoint Appoints Michael Campbell as Chief Commercial Officer

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

February is Age-related Macular Degeneration (AMD) and Low Vision Month at Prevent Blindness, Designed to Provide Helpful Sight-saving Resources and Support Programs

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)